Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef

Journal of Infectious Diseases

Volumn 190, Issue 11, 2004, Pages 1979-1988

  Fischer, Marek ^a   Joos, Beda ^a   Hirschel, Bernard ^b   Bleiber, Gabriela ^c   Weber, Rainer ^a   Günthard, Huldrych F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NEF PROTEIN; NELFINAVIR; REV PROTEIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TRANSACTIVATOR PROTEIN; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; MONONUCLEAR CELL; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; RECURRENT DISEASE; TREATMENT OUTCOME; VIREMIA; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELLS, CULTURED; DRUG THERAPY, COMBINATION; GENE PRODUCTS, NEF; GENE PRODUCTS, REV; GENE PRODUCTS, TAT; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; NEUTROPHILS; RECURRENCE; RNA SPLICING; RNA, VIRAL; VIRUS REPLICATION;

EID: 9444285887     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/425983     Document Type: Article

References (72)

1. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-91.
2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-9.
3. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-33.
4. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-8.
5. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94:13193-7.
6. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-300.
7. Wong JK, Hezareh M, Günthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-5.
8. Ho DD. Toward HIV eradication or remission: the tasks ahead. Science 1998; 280:1866-7.
9. Havlir DV, Strain MC, Clerici M, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77:11212-9.
10. Strain MC, Günthard HF, Havlir DV, et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci USA 2003; 100:4819-24.
11. Zhang L, Ramratnam B, Tenner RK, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340:1605-13.
12. Günthard HF, Frost SD, Leigh BA, et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 1999; 73:9404-12.
13. Günthard HF, Wong JK, Spina CA, et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 2000; 181:522-31.
14. Di Mascio M, Dornadula G, Zhang H, et al. In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 months. J Virol 2003; 77:2271-5.
15. Hermankova M, Ray SC, Ruff C, et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/mL receiving combination therapy. JAMA 2001; 286:196-207.
16. Fischer M, Wong JK, Russenberger D, et al. Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts. Antivir Ther 2002; 7:91-103.
17. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997; 276:960-4.
18. Fischer M, Joos B, Wong JK, et al. Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy. J Infect Dis 2004; 189:273-85.
19. Kuster H, Cone RC, Ott P, et al. Treatment-induced decline of HIV-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early HIV-1 infection. Am J Pathol 2000; 156:1973-86.
20. Persaud D, Zhou Y, Siliciano JM, Siliciano RF. Latency in human immunodeficiency virus type 1 infection: no easy answers. J Virol 2003; 77:1659-65.
21. Kulkosky J, Pomerantz RJ. Approaching eradication of highly active antiretroviral therapy: persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy. Clin Infect Dis 2002; 35:1520-6.
22. Joos B, Fischer M, Opravil M, Ott P, Weber R, Cone RC. Transient rebound of plasma HIV-1 RNA is not followed by repopulation of the lymphoid compartment with HIV-1 infected cells. AIDS 2000; 14:752-4.
23. + T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci USA 2003; 100: 1908-13.
24. Sanchez G, Xu X, Chermann JC, Hirsch I. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J Virol 1997; 71:2233-40.
25. Sharkey ME, Teo I, Greenough T, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med 2000; 6:76-81.
26. Fischer M, Trkola A, Joos B, et al. Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo. Antivir Ther 2003; 8:97-104.
27. Butler SL, Johnson E, Bushman FD. Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol 2002; 76:3739-47.
28. Pierson TC, Kieffer TL, Ruff CT, Buck C, Siliciano RF, Siliciano RF. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol 2002; 76:4138-44.
29. Brussel A, Mathez D, Broche-Pierre S, et al. Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection. AIDS 2003; 17:645-52.
30. Bushman F. Measuring covert HIV replication during HAART: the abundance of 2-LTR circles is not a reliable marker. AIDS 2003; 17:749-50.
31. Vesanen M, Markowitz M, Cao Y, Ho DD, Saksela K. Human immunodeficiency virus type-1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells. Virology 1997; 236:104-9.
32. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999; 340:1614-22.
33. Wong JK, Günthard HF, Havlir DV, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci USA 1997; 94:12574-9.
34. Günthard HF, Wong JK, Ignacio CC, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998; 72:2422-8.
35. Muesing MA, Smith DH, Cabradilla CD, Benton CV, Lasky LA, Capon DJ. Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature 1985; 313:450-8.
36. Sonza S, Mutimer HP, O'Brien K, et al. Selectively reduced tat mRNA heralds the decline in productive human immunodeficiency virus type 1 infection in monocyte-derived macrophages. J Virol 2002; 76:12611-21.
37. Arya SK, Guo C, Josephs SF, Wong SF. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 1985; 229:69-73.
38. Fisher AG, Feinberg MB, Josephs SF, et al. The trans-activator gene of HTLV-III is essential for virus replication. Nature 1986; 320:367-71.
39. Malim MH, Hauber J, Le SY, Maizel JV, Cullen BR. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 1989; 338:254-7.
40. Butera ST, Roberts BD, Lam L, Hodge T, Folks TM. Human immunodeficiency virus type 1 RNA expression by four chronically infected cell lines indicates multiple mechanisms of latency. J Virol 1994; 68:2726-30.
41. Terwilliger E, Sodroski JG, Rosen CA, Haseltine WA. Effects of mutations within the 3′ orf open reading frame region of human T-cell lymphotropic virus type III (HTLV-III/LAV) on replication and cytopathogenicity. J Virol 1986; 60:754-60.
42. Olivetta E, Percario Z, Fiorucci G, et al. HIV-1 Nef induces the release of inflammatory factors from human monocyte/macrophages: involvement of Nef endocytotic signals and NF-κB activation. J Immunol 2003; 170:1716-27.
43. Swingler S, Brichacek B, Jacque JM, Ulich C, Zhou J, Stevenson M. HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature 2003; 424:213-9.
44. Wang JK, Kiyokawa E, Verdin E, Trono D. The Nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc Natl Acad Sci USA 2000; 97:394-9.
45. Kim S, Ikeuchi K, Byrn R, Groopman J, Baltimore D. Lack of a negative influence on viral growth by the nef gene of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1989; 86:9544-8.
46. Miller MD, Warmerdam MT, Gaston I, Greene WC, Feinberg MB. The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med 1994; 179:101-13.
47. Spina CA, Kwoh TJ, Chowers MY, Guatelli JC, Richman DD. The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Med 1994; 179:115-23.
48. Trkola A, Kuster H, Leemann C, et al. Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflect capacity of immune system to improve viral set point. Blood 2004; 104:1784-92.
49. Metzner KJ, Bonhoeffer S, Fischer M, et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003; 188:1433-43.
50. Oxenius A, Price DA, Günthard HF, et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA 2002; 99:13747-52.
51. Fischer M, Hafner R, Schneider C, et al. HIV RNA in plasma rebounds within days during structured treatment interruptions. AIDS 2003; 17:195-9.
52. Fagard C, Lebraz M, Günthard HF, et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 2003; 163:1220-6.
53. + T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. J Virol 2002; 76:10169-76.
54. Trkola A, Kuster H, Leemann C, et al. Human immunodeficiency virus 1 fitness is a determining factor of viral rebound and set point in chronic infection. J Virol 2003; 77:13146-55.
55. Fischer M, Günthard HF, Opravil M, et al. Residual HIV-RNA levels persist for up to 2.5 years in PBMC of patients on potent antiretroviral therapy. AIDS Res Hum Retroviruses 2000; 16:1135-40.
56. Roscic-Mrkic B, Fischer M, Leemann C, et al. RANTES (CCL5) utilizes the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. Blood 2003; 102:1169-77.
57. Schwartz S, Felber BK, Benko DM, Fenyo EM, Pavlakis GN. Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1. J Virol 1990; 64:2519-29.
58. Saksela K, Muchmore E, Girard M, Fultz P, Baltimore D. High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees. J Virol 1993; 67:7423-7.
59. Fischer M, Huber W, Kallivroussis A, et al. Highly sensitive HIV-1 RNA quantitation from plasma, cells and tissues. J Clin Microbiol 1999; 37:1260-4.
60. Haase AT, Henry K, Zupancic M, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996; 274:985-9.
61. Kemal KS, Foley B, Burger H, et al. HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci USA 2003; 100:12972-7.
62. Venturi G, Catucci M, Romano L, et al. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis 2000; 181:740-5.
63. Ohagen A, Devitt A, Kunstman KJ, et al. Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol 2003; 77:12336-45.
64. Lewin SR, Vesanen M, Kostrikis L, et al. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol 1999; 73:6099-103.
65. Rampalli S, Kulkarni A, Kumar P, et al. Stimulation of Tat-independent transcriptional processivity from the HIV-1 LTR promoter by matrix attachment regions. Nucleic Acids Res 2003; 31:3248-56.
66. Yang X, Chen Y, Gabuzda D. ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-κB. J Biol Chem 1999; 274:27981-8.
67. Yedavalli VS, Benkirane M, Jeang KT. Tat and trans-activation-responsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires Sp1. J Biol Chem 2003; 278:6404-10.
68. Zhu M, Duan L, Pomerantz RJ. TAR- and Tat-independent replication of human immunodeficiency virus type 1 in human hepatoma cells. AIDS Res Hum Retroviruses 1996; 12:1093-101.
69. Andersson J, Fehniger TE, Patterson BK, et al. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS 1998; 12:F123-9.
70. Behbahani H, Landay A, Patterson BK, et al. Normalization of immune activation in lymphoid tissue following highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 25:150-6.
71. Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIV during opportunistic infections. Science 1997; 276:1857-61.
72. + T cells is markedly enhanced in the setting of antigen-specific immune activation. J Exp Med 1996; 183:687-92.